• Big data: helping patients and providers connect

    Life sciences companies are under increasing pressure to do more with less. See how digital strategies and accountability with analytics help bridge the communication gap.

  • Pharmaceutical R&D tax incentives

    Globalization of the pharmaceutical industry and increased outsourcing have drastically changed the R&D landscape. Our report explores the impact on R&D tax incentives.

  • Megatrends - Health reimagined

    Health care is embarking on a once-in-a-lifetime transformation. This report explores what the industry needs to do to achieve future success.

  • The new revenue recognition standard - life sciences

    Due to the revenue recognition standards recently issued, life sciences entities may need to make changes. We highlight the key considerations and next steps.

  • New horizons: health care industry report 2014

    A profound shift is happening in the US health care system. In this edition, we explore ways the industry is becoming more anchored in value.

  • Beyond borders: unlocking value

    With double-digit revenue growth and a sharp rise in funds raised, the global biotechnology industry rebounded strongly this year. Find out more in our annual report.

  • Biotechnology in Europe

    This joint EuropaBio and EY report analyzes current tax, finance and regulatory regimes for the biotech sector in Europe and details country-specific guidelines and incentives.

  • Life sciences: preparing for big data and analytics

    Many life sciences organizations are not capturing and applying value from analytics in a meaningful way. Gain the edge by harnessing today’s big data insights.

  • Working capital report - Cash on prescription

    Pharma saw improved working capital performance in 2013, but progress has not been sufficient to reverse deterioration of previous years. Our report explores.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences network brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:

  • Biotechnology

    More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.

    But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.

    We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.

    We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.

    So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.

    Related content:

  • Pharmaceutical

    Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.

    We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.

    Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders — patients, providers, manufacturers and others — around these interventions.

    Related content:

  • Medical technology

    Fundamental drivers — from aging populations and increasingly prevalent chronic diseases to expanding needs for lifestyle medical procedures — suggest demand for medical technology products should be robust for years to come.

    Still, the road ahead is littered with risks and challenges. Within an industry that requires constant innovation, you’re under pressure to demonstrate value for the products you develop, comply with increased regulations and satisfy the demanding new consumer-turned-competitor.

    Not only are we the firm of choice for medtechs entering the public markets, we also audit more medtech companies that are tracked by the Russell 3000 and Standard & Poor’s than any other professional services firm.

    From venture funding and IPOs to initial product launches and global expansions, we have the proven experience to help medical technology organizations navigate every critical stage of their business life cycle.

    Related content:

Contact us

Lara Iob    Lara Iob 
Life Sciences
514 879 6514

Connect with us

EY - Health Care Advisory Services

Health Care Advisory Services

Driving sustainable excellence in health care.

EY Life Sciences: Building a better working world

EY Life Sciences: Building a better working world

Empowered patients are demanding more. Big data and supply chains offer new challenges. EY has the vision to help solve the industry's most pressing issues.